The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy
Recruiting · NCT02573636 · Observational (researchers observe without assigning treatment) · Lead sponsor: Sir Mortimer B. Davis - Jewish General Hospital
View the official record on ClinicalTrials.gov →What this trial is about
The objective of the study is to evaluate the predictive value of TMPRSS2-ERG gene fusion and PTEN in patients with high risk prostate cancer treated with first line LHRH agonist after biochemical failure.
Who can take part
Age range
18 Years and older
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- T3a +
- PSA \> 20
- Gleason 8 or higher
- Karnofsky performance status ≥ 70.
- Signed study-specific informed consent
Where it is running
9 locations listed.
- CIUSSS du Saguenay-Lac-St-Jean/CSSS de Chicoutimi - Chicoutimi, Quebec, Canada
- CISSS de la Montérégie-Centre - Hôpital Charles-LeMoyne - Greenfield Park, Quebec, Canada
- CISSS de Laval - Hôpital de la Cité-de-la-santé de Laval - Laval, Quebec, Canada
- CIUSSS de l'Est-de-l'Île-de-Montréal - Hôpital Maisonneuve-Rosemont - Montreal, Quebec, Canada
- Jewish General Hospital, McGill University - Montreal, Quebec, Canada
- MUHC - Cedars Cancer Center - Montreal, Quebec, Canada
- CHU - L'Hôtel-Dieu de Québec - Québec, Quebec, Canada
- CIUSSS de l'Estrie - Hôpital Fleurimont - Sherbrooke, Quebec, Canada
- CIUSSS de la Mauricie-et-du-centre-du Quebec - Centre hospitalier régional de Trois-Rivières - Trois-Rivières, Quebec, Canada